519PFOLFOXIRI + BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): FINAL SURVIVAL AND PHARMACOGENOMIC PROFILING RESULTS FROM THE OPAL STUDY

Abstract Aim: The addition of BEV to standard doublet chemotherapy (CT) improves outcomes vs CT alone in pts with mCRC. Use of more intensive triplet CT may prolong overall survival (OS), progression-free survival (PFS), increase response rates and improve resectability rates but at the expense of g...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2014-09, Vol.25 (suppl_4), p.iv176-iv176
Hauptverfasser:	Stein, A., Atanackovic, D., Stoehlmacher, J., Hildebrandt, B., Stübs, P., Steffens, C., Brugger, W., Hapke, G., Illerhaus, G., Bluemner, E., Bokemeyer, C.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!